What Baijun Biotech does

Baijun Biotechnology, operating commercially as BioMetas, is a Shanghai-based biopharmaceutical contract research and manufacturing services provider founded in 2022 and headquartered at 334 Aidisheng Road, Pudong New Area. The company operates with a 101-250 employee headcount and runs an integrated CRO/CDMO platform serving pharmaceutical and biotechnology clients across the biologics development lifecycle, from target discovery through clinical and commercial manufacturing. The offering spans discovery biologics (recombinant antibody/protein production leveraging the proprietary MetaCHO platform), biology and pharmacology (oncology, immunology, inflammation), DMPK and exploratory toxicology for both small and large molecules, immunology services, in vitro biology, cancer cell biology (with a bank of ~900 cancer cell lines), and in vivo pharmacology featuring 200+ CDX tumor models across 26 cancer types and 9 syngeneic models.

The company's manufacturing arm is supported by GMP and PIC/S certified commercial production lines ranging from 3x1500L to 3x5000L bioreactors, providing tech-transfer, biosimilar clinical production, and fill-finish (DP/DS, LYO, PFS) services. Specialized platforms include the MetaCHO protein/antibody production system and a PD-1 biosimilar development platform aimed at cost-effective antibody therapeutics. BioMetas also runs an AAALAC-accredited preclinical operation and participates in international industry venues such as RESI Europe.

BioMetas monetizes through four revenue streams: (1) professional services CRO contracts (Discovery Biologics, DMPK, Toxicology, Immunology, In Vivo Pharmacology, etc.) priced on a multi-year contract basis; (2) managed services CDMO contracts for clinical and commercial biologics manufacturing; (3) one-time catalog sales of off-the-shelf biosimilar antibodies, recombinant proteins, cytokines, and antigens priced at ¥1,200-¥25,000 per unit through an online storefront; and (4) a Biotech Accelerator program with CFS Capital that provides CRO/CMC/CDMO services to early-stage startups (e.g., MindRank, Anji Pharma, Arthrosi Therapeutics, 3D Medicines, Acelink Therapeutics) in exchange for equity stakes. The accelerator has onboarded 100+ ventures to date. The company completed a Pre-A funding round of tens of millions of yuan in September 2024 led by Huagai Capital (with Hongbo Pharmaceutical participating) and secured a follow-on financing in January 2026 led by Hefei Life and Health Venture Capital Partnership.

Name

Baijun Biotech

Website

https://biometasgroup.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

101–250 employees

Short description

Baijun Biotechnology (BioMetas) is a Shanghai-based CRO/CDMO providing integrated biologics discovery, preclinical research, and GMP manufacturing services to pharma and biotech clients, with an equity-for-service biotech accelerator run jointly with CFS Capital.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Research and Manufacturing Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

Keywords

• Biologics CRO services
• CDMO manufacturing
• Recombinant antibody production
• Preclinical drug discovery
• Biosimilar development

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. CRO Services: Contract research services including Discovery Biologics, Biology & Pharmacology, DMPK, Toxicology, Immunology, In Vitro Biology, Cancer Cell Biology, and In Vivo Pharmacology services provided to pharma and biotech clients
2. CDMO Manufacturing: Contract manufacturing services for clinical and commercial biologics production, including technology transfer, GMP production, and filling/packaging services
3. Biologics Product Catalog: Sale of off-the-shelf recombinant antibodies, proteins, cytokines, antigens, and biosimilar products for research use
4. Biotech Accelerator Program: Equity-for-service model providing CRO, CMC, and CDMO services to biotech startups in exchange for equity stakes

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Baijun Biotech (BioMetas) is a biopharmaceutical R&D services company providing integrated CRO contract research services spanning biologics discovery, protein science, immunology, in vitro biology, in vivo pharmacology, cancer cell biology, and DMPK/toxicology, alongside CDMO GMP-certified manufacturing services for clinical and commercial biologics production. The firm also operates an online catalog of off-the-shelf biosimilar antibodies, recombinant proteins, cytokines, and antigens for research use, and runs a biotech accelerator program in partnership with CFS Capital that delivers CRO/CMC/CDMO services to startups in exchange for equity.

Product overview

BioMetas (Baijun Biotech) is a biologics and contract research organization (CRO) providing integrated drug discovery and development services. The company operates through three main divisions: Discovery Biologics CRO Services (encompassing molecular biology, protein science, immunology, in vitro biology, in vivo pharmacology, and cancer cell biology), Biologics CDMO Manufacturing Services (GMP-certified production), and a Biologics Product Catalog (offering off-the-shelf recombinant antibodies, biosimilar antibodies, cytokines, and antigens for research use). The company also operates a Biotech Accelerator program using an equity-for-service model in partnership with CFS Capital. Key platforms include the MetaCHO platform for recombinant protein production and specialized PD-1 biosimilar development platform. The company has partnerships with China-based CDMOs and maintains over 100 accelerated ventures through its accelerator program.

Differentiator

Problem solved

Functional benefit

Products and services

• Discovery Biologics World-leading biologics technology platform providing a comprehensive service portfolio from conceptual to clinically proven biology, using innovative technologies for biologics discovery for pharma and biotech clients.
• Biology & Pharmacology CRO service specializing in key bio-therapeutic areas including oncology, cell biology, immunology, and inflammation, with innovative analysis tools for compound assessment.
• DMPK & Exploratory Toxicology Bespoke drug metabolism and pharmacokinetics and toxicity studies tailored to each unique compound, including LC-MS/MS analysis for small molecules, ELISA for large molecules, rodent and large animal studies, bioanalysis, and PK analysis, designed to fast-track development to clinical stages.
• Protein Science (Recombinant Antibody and Protein Production) Protein and antibody design and production services including bacterial, insect cell, and mammalian cell expression, leveraging the MetaCHO platform technology for faster and more economical production of customer proteins and antibodies.
• Immunology Services Portfolio of models and analysis tools for oncology, inflammation, and autoimmune research including in vitro assays covering PBMC/blood, T cell, B/NK cell, and monocyte assays, plus ex vivo PD analysis with multi-species support.
• In Vitro Biology High-throughput screening and compound screening capabilities including biochemistry/enzymology assays covering kinases, metabolic enzymes, epigenetic enzymes, helicases, E3 ligases, and GTPases, using AlphaLISA, TR-FRET, and thermal shift assay technologies.
• In Vivo Pharmacology In vivo pharmacology services providing CDX tumor models (26 cancer types, 200+ models), syngeneic tumor models (9 cancer types), and autoimmune disease models with humanized immune system capabilities.
• Cancer Cell Biology CRISPR library screening (600+ banked cell lines), cancer cell line panel screening, target validation, stable cell line generation, and cell-based assays including 3D assays, supported by a bank of 900+ cancer cell lines.
• PD-1 Biosimilar Development Platform Biosimilar development platform designed to fast-track PD-1/PDL1 targeting antibody development and make PD-1/PD-L1 drugs more accessible and cost-effective globally for clients.
• CDMO Manufacturing Services Contract Development and Manufacturing Organization services including technology transfer R&D, GMP & PIC/s certified commercial production (3x1500L to 3x5000L bioreactors), biosimilar clinical production, and fill-finish solutions (DP/DS, LYO, PFS) for clinical and commercial biologics.
• Biotech Accelerator Program Equity-for-service program providing CRO, CMC, and CDMO services to biotech startups in exchange for equity stakes, in partnership with CFS Capital. The program has accelerated over 100 ventures and provides access to both BioMetas and CFS Capital's scientific experts and global VC network.
• Biosimilar Antibodies Catalog Large catalog of off-the-shelf biosimilar antibodies including Erfonrilimab (KN-046), Glofitamab, Teclistamab, Trastuzumab, Ranibizumab, Ravulizumab, Zolbetuximab, and 50+ other therapeutic antibody biosimilars sold in tiered sizes (1mg to 100mg) for research use.
• In Vivo Antibodies Catalog In vivo grade antibodies including 10F.9G2-mIgG1, 10F.9G2-ratIgG2b, and RMP1-14-mIgG1, offered in tiered sizes for preclinical research applications.
• Ras-related Proteins Catalog Recombinant Ras-related proteins including His-tagged KRAS G12D, G12V, G12R, G13D, NRAS Q61L, and SOS1 for cancer research applications.
• Cytokine Proteins Catalog Comprehensive catalog of recombinant cytokine proteins including interleukins (IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-15, IL-23), interferons (IFNa, IFNg), TNFa, GM-CSF, M-CSF, SCF, and EGF for research applications.
• Antigen Proteins Catalog Recombinant antigen proteins including hBCMA, hCD19, hCD3e, hCD3d, hEGFR, hHER2-ECD, hPDL1, hVEGF165, and HLA-A*02:01 & B2M complex for research applications.

Quantifiable outcome

• 200+ in vivo tumor models available for client projects
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core, minor and supporting.

• CFS CapitalcoreStrategic or Co-development PartnerCFS Capital is a life sciences venture capital fund in Asia that partners with BioMetas for the Biotech Accelerator program. Together they have accelerated over 100 ventures. CFS provides access to their network of VC funds and scientific experts from San Jose to Shanghai. The accelerator offers ventures access to both BioMetas and CFS Capital's scientific experts and global network.
• Accelerator Portfolio CompaniesminorOthersCompanies accelerated through the BioMetas-CFS Capital accelerator program including MindRank, Anji Pharma, Arthrosi Therapeutics, 3D Medicines, and Acelink Therapeutics. These companies receive CRO, CMC, and CDMO services in exchange for equity stakes.
• China-based CDMOssupportingStrategic or Co-development PartnerBioMetas partners with state-of-the-art China-based CDMOs for production needs including clinical and commercial batches for orphan drugs. Partner facilities equipped with latest IOT technologies for efficient production timelines and quality.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• GenScript ProBio: Biologics CDMO arm of GenScript offering GMP manufacturing, cell line development, and process development. Directly competes with BioMetas' CDMO services and shares the biosimilar/recombinant protein production overlap.
• GenScript: Global biologics-focused CRO/CDMO with a reagent catalog and discovery through manufacturing services, plus a biotech venture arm. Direct overlap with BioMetas across recombinant protein/antibody production, biosimilar catalog, and integrated biologics platform.
• Sino Biological: Chinese reagent supplier offering recombinant proteins, antibodies, and cytokines for research use. Direct competitor to BioMetas' off-the-shelf biologics catalog and biosimilar antibody product line.
• Crown Bioscience: Preclinical CRO specializing in in vivo pharmacology, oncology models (CDX, syngeneic, humanized), and translational research. Directly overlaps with BioMetas' In Vivo Pharmacology platform offering 200+ CDX models.
• ChemPartner: China-headquartered CRO/CDMO providing drug discovery, biology, DMPK, and biologics manufacturing services. Comparable integrated service platform with similar Chinese customer base.
• Shanghai Medicilon: China-based preclinical CRO offering DMPK, toxicology, in vivo pharmacology, and biologics services. Direct competitor to BioMetas' preclinical CRO offering and similar Chinese customer base.
• Pharmaron: China-headquartered CRO/CDMO offering drug discovery, preclinical, and biologics manufacturing services. Direct competitor across BioMetas' discovery biology, DMPK, and CDMO service lines, with significantly larger scale.

Broad incumbents

• WuXi Biologics: The dominant global biologics CDMO and CRO, headquartered in China with end-to-end discovery, development, and manufacturing services. WuXi Biologics is the benchmark against which all Chinese biologics CDMOs (including BioMetas) are measured, with vastly greater scale and regulatory history.

Regional players

• Tigermed: Leading Chinese clinical CRO with growing preclinical and biologics services. Overlaps with BioMetas in serving Chinese pharma/biotech clients but skews more toward clinical-stage services.

Emerging players

• AbCellera: Canadian biologics discovery CRO with antibody platform technology and growing CDMO capabilities. Comparable business model around biologics discovery and antibody production, but with different geographic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baijun Biotech